Download PDF
Semin Respir Crit Care Med 2019; 40(03): 394-401
DOI: 10.1055/s-0039-1695058
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

What's the Score? Do Pleural Effusion Clinical Scoring Systems Help in Management of Disease?

Peter Grendelmeier
1   Oxford Respiratory Trials Unit, Oxford Centre for Respiratory Medicine, Nuffield Department of Medicine, University of Oxford, Churchill Hospital Site, Oxford, England, United Kingdom
,
Najib M. Rahman
1   Oxford Respiratory Trials Unit, Oxford Centre for Respiratory Medicine, Nuffield Department of Medicine, University of Oxford, Churchill Hospital Site, Oxford, England, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
16 September 2019 (online)

    Permissions and Reprints

Abstract

Pleural effusion is a common condition, affecting over 3,000 people per million population every year. More than 50 causes of pleural effusions are known, including pleural infection and malignant pleural disease. These conditions place a large burden on healthcare systems with one-fourth of patients with pleural infection having a length of hospital stay of more than 1 month. Malignant pleural effusion represents advanced malignant disease with a correspondingly high mortality. Prognostic models using clinical information in combination with blood or pleural fluid biomarkers predicting survival and other outcome measures are therefore a priority in improving clinical care, and potentially outcomes. Identifying patients with poor prognosis may help avoid discomfort and unnecessary interventions at the end of their lives, while, on the other hand, individuals with scores predicting a particularly good prognosis might be selected for more aggressive early treatment. Such scores must be based on data representing routine practice in a general hospital and variables chosen based on their clinical availability at clinical decision points (i.e., before treatment is instituted), making the findings widely applicable.

Keywords

pleural effusion - scores - prognosis - management - pleural infection - malignant disease - LENT - PROMISE
 

  • References

  • 1 Mercer RM, Psallidas I, Rahman NM. Ultrasound in the management of pleural disease. Expert Rev Respir Med 2017; 11 (04) 323-331
    CrossrefPubMedGoogle Scholar
  • 2 Bhatnagar R, Maskell N. The modern diagnosis and management of pleural effusions. BMJ 2015; 351: h4520
    PubMedGoogle Scholar
  • 3 Taghizadeh N, Fortin M, Tremblay A. US hospitalizations for malignant pleural effusions: data from the 2012 National Inpatient Sample. Chest 2017; 151 (04) 845-854
    CrossrefPubMedGoogle Scholar
  • 4 Rahman NM, Kahan BC, Miller RF, Gleeson FV, Nunn AJ, Maskell NA. A clinical score (RAPID) to identify those at risk for poor outcome at presentation in patients with pleural infection. Chest 2014; 145 (04) 848-855
    CrossrefPubMedGoogle Scholar
  • 5 Psallidas I, Kanellakis NI, Gerry S. , et al. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. Lancet Oncol 2018; 19 (07) 930-939
    CrossrefPubMedGoogle Scholar
  • 6 Clive AO, Kahan BC, Hooper CE. , et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 2014; 69 (12) 1098-1104
    CrossrefPubMedGoogle Scholar
  • 7 Psallidas I, Yousuf A, Talwar A. , et al. Assessment of patient-reported outcome measures in pleural interventions. BMJ Open Respir Res 2017; 4 (01) e000171
    CrossrefPubMedGoogle Scholar
  • 8 Mishra EK, Clive AO, Wills GH. , et al. Randomized controlled trial of urokinase versus placebo for nondraining malignant pleural effusion. Am J Respir Crit Care Med 2018; 197 (04) 502-508
    CrossrefPubMedGoogle Scholar
  • 9 Llamas-Álvarez AM, Tenza-Lozano EM, Latour-Pérez J. Diaphragm and lung ultrasound to predict weaning outcome: systematic review and meta-analysis. Chest 2017; 152 (06) 1140-1150
    CrossrefPubMedGoogle Scholar
  • 10 Wang JS, Tseng CH. Changes in pulmonary mechanics and gas exchange after thoracentesis on patients with inversion of a hemidiaphragm secondary to large pleural effusion. Chest 1995; 107 (06) 1610-1614
    CrossrefPubMedGoogle Scholar
  • 11 Wang LM, Cherng JM, Wang JS. Improved lung function after thoracocentesis in patients with paradoxical movement of a hemidiaphragm secondary to a large pleural effusion. Respirology 2007; 12 (05) 719-723
    CrossrefPubMedGoogle Scholar
  • 12 Salamonsen MR, Lo AKC, Ng ACT, Bashirzadeh F, Wang WYS, Fielding DIK. Novel use of pleural ultrasound can identify malignant entrapped lung prior to effusion drainage. Chest 2014; 146 (05) 1286-1293
    CrossrefPubMedGoogle Scholar
  • 13 American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000; 162 (05) 1987-2001
    CrossrefPubMedGoogle Scholar
  • 14 Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. ; BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 (Suppl. 02) ii32-ii40
    PubMedGoogle Scholar
  • 15 Davies HE, Lee YC. Management of malignant pleural effusions: questions that need answers. Curr Opin Pulm Med 2013; 19 (04) 374-379
    CrossrefPubMedGoogle Scholar
  • 16 Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: from bench to bedside. Eur Respir Rev 2016; 25 (140) 189-198
    CrossrefPubMedGoogle Scholar
  • 17 Rahman NM, Pepperell J, Rehal S. , et al. Effect of opioids vs NSAIDs and larger vs smaller chest tube size on pain control and pleurodesis efficacy among patients with malignant pleural effusion: the TIME1 randomized clinical trial. JAMA 2015; 314 (24) 2641-2653
    CrossrefPubMedGoogle Scholar
  • 18 Pilling JE, Dusmet ME, Ladas G, Goldstraw P. Prognostic factors for survival after surgical palliation of malignant pleural effusion. J Thorac Oncol 2010; 5 (10) 1544-1550
    CrossrefPubMedGoogle Scholar
  • 19 Bielsa S, Salud A, Martínez M. , et al. Prognostic significance of pleural fluid data in patients with malignant effusion. Eur J Intern Med 2008; 19 (05) 334-339
    CrossrefPubMedGoogle Scholar
  • 20 Ozyurtkan MO, Balci AE, Cakmak M. Predictors of mortality within three months in the patients with malignant pleural effusion. Eur J Intern Med 2010; 21 (01) 30-34
    CrossrefPubMedGoogle Scholar
  • 21 Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000; 117 (01) 73-78
    CrossrefPubMedGoogle Scholar
  • 22 Proctor MJ, Morrison DS, Talwar D. , et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011; 47 (17) 2633-2641
    CrossrefPubMedGoogle Scholar
  • 23 Kao SC, Pavlakis N, Harvie R. , et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010; 16 (23) 5805-5813
    CrossrefPubMedGoogle Scholar
  • 24 Pinato DJ, Mauri FA, Ramakrishnan R, Wahab L, Lloyd T, Sharma R. Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol 2012; 7 (03) 587-594
    CrossrefPubMedGoogle Scholar
  • 25 Davies HE, Mishra EK, Kahan BC. , et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 2012; 307 (22) 2383-2389
    CrossrefPubMedGoogle Scholar
  • 26 Psallidas I, Piotrowska HEG, Yousuf A. , et al. Efficacy of sonographic and biological pleurodesis indicators of malignant pleural effusion (SIMPLE): protocol of a randomised controlled trial. BMJ Open Respir Res 2017; 4 (01) e000225
    PubMedGoogle Scholar
  • 27 Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 2006; 29 (05) 829-838
    CrossrefPubMedGoogle Scholar
  • 28 Feller-Kopman DJ, Reddy CB, DeCamp MM. , et al. Management of malignant pleural effusions. An official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med 2018; 198 (07) 839-849
    CrossrefPubMedGoogle Scholar
  • 29 Clive AO, Jones HE, Bhatnagar R, Preston NJ, Maskell N. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev 2016; (05) CD010529
    PubMedGoogle Scholar
  • 30 Corcoran JP, Hallifax RJ, Mercer RM. , et al. Thoracic Ultrasound as an Early Predictor of Pleurodesis Success in Malignant Pleural Effusion. Chest 2018; 154 (05) 1115-1120
    CrossrefPubMedGoogle Scholar
  • 31 Zhu Z, Donnelly E, Dikensoy O. , et al. Efficacy of ultrasound in the diagnosis of pleurodesis in rabbits. Chest 2005; 128 (02) 934-939
    CrossrefPubMedGoogle Scholar
  • 32 The efficacy of sonographic and biological pleurodesis indicators of malignant pleural effusion (SIMPLE). Available at: https://doi.org/10.1186/ISRCTN16441661 . Accessed July 31, 2019
    CrossrefPubMed
  • 33 Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med 1980; 69 (04) 507-512
    CrossrefPubMedGoogle Scholar
  • 34 Maskell NA, Davies CWH, Nunn AJ. , et al; First Multicenter Intrapleural Sepsis Trial (MIST1) Group. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005; 352 (09) 865-874
    CrossrefPubMedGoogle Scholar
  • 35 Finley C, Clifton J, Fitzgerald JM, Yee J. Empyema: an increasing concern in Canada. Can Respir J 2008; 15 (02) 85-89
    CrossrefPubMedGoogle Scholar
  • 36 Farjah F, Symons RG, Krishnadasan B, Wood DE, Flum DR. Management of pleural space infections: a population-based analysis. J Thorac Cardiovasc Surg 2007; 133 (02) 346-351
    CrossrefPubMedGoogle Scholar
  • 37 Davies CW, Kearney SE, Gleeson FV, Davies RJ. Predictors of outcome and long-term survival in patients with pleural infection. Am J Respir Crit Care Med 1999; 160 (5, Pt 1): 1682-1687
    CrossrefPubMedGoogle Scholar
  • 38 Rahman NM, Maskell NA, West A. , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 2011; 365 (06) 518-526
    CrossrefPubMedGoogle Scholar
  • 39 Corcoran JP, Wrightson JM, Belcher E, DeCamp MM, Feller-Kopman D, Rahman NM. Pleural infection: past, present, and future directions. Lancet Respir Med 2015; 3 (07) 563-577
    CrossrefPubMedGoogle Scholar
  • 40 Podbielski FJ, Maniar HS, Rodriguez HE, Hernan MJ, Vigneswaran WT. Surgical strategy of complex empyema thoracis. JSLS 2000; 4 (04) 287-290
    PubMedGoogle Scholar
  • 41 Cunniffe MG, Maguire D, McAnena OJ, Johnston S, Gilmartin JJ. Video-assisted thoracoscopic surgery in the management of loculated empyema. Surg Endosc 2000; 14 (02) 175-178
    CrossrefPubMedGoogle Scholar
  • 42 Waller DA, Rengarajan A, Nicholson FH, Rajesh PB. Delayed referral reduces the success of video-assisted thoracoscopic debridement for post-pneumonic empyema. Respir Med 2001; 95 (10) 836-840
    CrossrefPubMedGoogle Scholar
  • 43 Allen MS, Deschamps C, Jones DM, Trastek VF, Pairolero PC. Video-assisted thoracic surgical procedures: the Mayo experience. Mayo Clin Proc 1996; 71 (04) 351-359
    CrossrefPubMedGoogle Scholar
  • 44 Perttunen K, Tasmuth T, Kalso E. Chronic pain after thoracic surgery: a follow-up study. Acta Anaesthesiol Scand 1999; 43 (05) 563-567
    CrossrefPubMedGoogle Scholar
  • 45 Jiménez Castro D, Díaz G, Pérez-Rodríguez E, Light RW. Prognostic features of residual pleural thickening in parapneumonic pleural effusions. Eur Respir J 2003; 21 (06) 952-955
    CrossrefPubMedGoogle Scholar
  • 46 The Pleural Infection Longitudinal Outcome Study. Available at: https://doi.org/10.1186/ISRCTN50236700 . Accessed July 31, 2019
    CrossrefPubMed
  • 47 Porcel JM. Pleural effusions from congestive heart failure. Semin Respir Crit Care Med 2010; 31 (06) 689-697
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Porcel JM, Ferreiro L, Civit C. , et al. Development and validation of a scoring system for the identification of pleural exudates of cardiac origin. Eur J Intern Med 2018; 50: 60-64
    CrossrefPubMedGoogle Scholar
  • 49 Light RW, Macgregor MI, Luchsinger PC, Ball Jr WC. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972; 77 (04) 507-513
    CrossrefPubMedGoogle Scholar
  • 50 Bielsa S, Porcel JM, Castellote J, Mas E, Esquerda A, Light RW. Solving the Light's criteria misclassification rate of cardiac and hepatic transudates. Respirology 2012; 17 (04) 721-726
    CrossrefPubMedGoogle Scholar
  • 51 Porcel JM, Chorda J, Cao G, Esquerda A, Ruiz-González A, Vives M. Comparing serum and pleural fluid pro-brain natriuretic peptide (NT-proBNP) levels with pleural-to-serum albumin gradient for the identification of cardiac effusions misclassified by Light's criteria. Respirology 2007; 12 (05) 654-659
    CrossrefPubMedGoogle Scholar
  • 52 Romero-Candeira S, Hernández L, Romero-Brufao S, Orts D, Fernández C, Martín C. Is it meaningful to use biochemical parameters to discriminate between transudative and exudative pleural effusions?. Chest 2002; 122 (05) 1524-1529
    CrossrefPubMedGoogle Scholar
  • 53 Porcel JM, Vives M, Cao G, Esquerda A, Rubio M, Rivas MC. Measurement of pro-brain natriuretic peptide in pleural fluid for the diagnosis of pleural effusions due to heart failure. Am J Med 2004; 116 (06) 417-420
    CrossrefPubMedGoogle Scholar
  • 54 Porcel JM, Martínez-Alonso M, Cao G, Bielsa S, Sopena A, Esquerda A. Biomarkers of heart failure in pleural fluid. Chest 2009; 136 (03) 671-677
    CrossrefPubMedGoogle Scholar